Iluvien

Fluocinolone Acetonide, the active ingredient in Iluvien, is a glucocorticoid presented as a 0.19 mg sustained‑release intravitreal implant for intravitreal use. It treats chronic diabetic macular edema in adults, delivering long‑term anti‑inflammatory action directly to the retina. The implant provides continuous low‑dose release over up to 36 months, reducing the need for frequent injections.

GNH USA supplies Iluvien as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, ophthalmology clinics, and procurement teams worldwide, ensuring reliable global distribution and regulatory compliance.

Iluvien, a sustained‑release glucocorticoid implant, is indicated for chronic diabetic macular edema, a condition characterized by retinal swelling due to diabetes.

- Chronic diabetic macular edema: reduces retinal fluid accumulation and improves visual acuity in patients with persistent disease despite other therapies. - Diabetic macular edema unresponsive to anti‑VEGF therapy: provides an alternative corticosteroid option for eyes that have not responded adequately to anti‑VEGF agents. - Diabetic macular edema in pseudophakic eyes: offers benefit without adding cataract risk in patients who have already undergone lens replacement.

Iluvien may be associated with ocular and systemic adverse reactions, which are categorized by frequency.

Common Side Effects: - Increased intraocular pressure: may require topical or surgical management. - Cataract formation: accelerated lens opacity in phakic eyes. - Vitreous hemorrhage: bleeding within the vitreous cavity. - Ocular inflammation: mild anterior chamber reaction. - Floaters: perception of moving spots in vision. - Transient reduction in visual acuity: short‑term worsening after implantation.

Serious or Rare Side Effects: - Endophthalmitis: severe intraocular infection requiring urgent treatment. - Retinal detachment: separation of retinal layers that can threaten vision. - Implant migration: displacement of the device to an unintended ocular location. - Severe ocular hypertension: pressure elevation unresponsive to medication. - Optic nerve damage: rare ischemic injury. - Systemic corticosteroid effects: possible hyperglycemia or adrenal suppression in susceptible patients.

Prior to Iluvien implantation, clinicians should assess ocular health and monitor for potential complications.

- Monitor intraocular pressure: schedule regular tonometry checks. - Assess cataract status: evaluate lens clarity before and after treatment. - Screen for ocular infection: avoid implantation in the presence of active infection. - Use caution in glaucoma patients: heightened risk of pressure spikes. - Evaluate systemic steroid exposure: consider cumulative corticosteroid load. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Iluvien may interact with other ocular or systemic therapies that influence inflammation or intraocular pressure.

Major Interactions (Avoid): - Concomitant intraocular corticosteroids: risk of additive pressure elevation and cataract formation. - Systemic immunosuppressants: increased susceptibility to ocular infection.

Moderate Interactions (Monitor Closely): - Topical ocular NSAIDs: may potentiate intraocular pressure changes. - Systemic CYP3A4 inducers: could modestly reduce local drug exposure. - Anticoagulants: may increase risk of intraocular hemorrhage during implantation. - Other intraocular devices: assess compatibility to prevent mechanical interference.